Literature DB >> 24566817

Expert consensus document: A consensus on the medical treatment of acromegaly.

Andrea Giustina1, Philippe Chanson2, David Kleinberg3, Marcello D Bronstein4, David R Clemmons5, Anne Klibanski6, Aart J van der Lely7, Christian J Strasburger8, Steven W Lamberts7, Ken K Y Ho9, Felipe F Casanueva10, Shlomo Melmed11.   

Abstract

In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24566817     DOI： 10.1038/nrendo.2014.21

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  74 in total

1.  Experience from the Argentine Pegvisomant Observational Study: preliminary data.

Authors:  N García Basavilbaso; M Guitelman; A Nagelberg; G Stalldecker; A Carabelli; O Bruno; K Danilowitz; M Manavela; S Mallea Gil; C Ballarino; R Guelman; D Katz; S Fidalgo; R Leal; H Fideleff; M Servidio; D Bruera; F Librandi; A Chervin; M Vitale; A Basso
Journal:  Front Horm Res       Date:  2010-07-05       Impact factor: 2.606

Review 2.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

4.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

5.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

6.  Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Authors:  J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-11-17       Impact factor: 2.949

7.  Lipodystrophy in patients with acromegaly receiving pegvisomant.

Authors:  Vivien S Bonert; Laurence Kennedy; Stephan Petersenn; Ariel Barkan; John Carmichael; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2008-07-08       Impact factor: 5.958

8.  Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence.

Authors:  Hervé Gouya; Olivier Vignaux; Patrick Le Roux; Philippe Chanson; Jérome Bertherat; Xavier Bertagna; Paul Legmann
Journal:  AJR Am J Roentgenol       Date:  2008-06       Impact factor: 3.959

Review 9.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

Review 10.  Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.

Authors:  Francisco Pita-Gutierrez; Sonia Pertega-Diaz; Salvador Pita-Fernandez; Lara Pena; Gloria Lugo; Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240
View more
  109 in total

1.  Fractionated stereotactic radiotherapy: an interesting alternative to stereotactic radiosurgery in acromegaly.

Authors:  Emmanuelle Kuhn; Philippe Chanson
Journal:  Endocrine       Date:  2015-10-13       Impact factor: 3.633

2.  Treatment of pituitary tumours in 2014: Advances in therapy of adenomas secreting GH, ACTH and TSH.

Authors:  Annamaria Colao
Journal:  Nat Rev Endocrinol       Date:  2014-12-23       Impact factor: 43.330

3.  ACROSTUDY: the Italian experience.

Authors:  S Grottoli; P Maffei; F Bogazzi; S Cannavò; A Colao; E Ghigo; R Gomez; E Graziano; M Monterubbianesi; P Jonsson; L De Marinis
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

4.  CAD/CAM Engineered Patient-Specific Impants as a Reposition Device in Le Fort I and Modified Subcondylar Osteotomies: Case Report of Facial Deformity Correction in Acromegaly.

Authors:  Juho Suojanen; Zlatan Hodzic; Tuula Palotie; Patricia Stoor
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-07-06

5.  How to improve effectiveness of pegvisomant treatment in acromegalic patients.

Authors:  M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo
Journal:  J Endocrinol Invest       Date:  2017-10-28       Impact factor: 4.256

Review 6.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

7.  Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.

Authors:  Vivien Bonert; John Carmichael; Zengru Wu; James Mirocha; Daniel A Perez; Nigel J Clarke; Richard E Reitz; Michael J McPhaul; Adam Mamelak
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

8.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 9.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

Review 10.  New therapeutic agents for acromegaly.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2015-11-27       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.